Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Gdansk
Clinical trial register · Poland

Clinical Trials in Gdansk, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 27 Krakow 21 Lodz 21 Poznan 20 Gdansk 20
Narrow the registerReset
Recruitment status
Phase
Site location
Warsaw27 Krakow21 Lodz21 Poznan20 Gdansk20
All 40 locations
Target enrolment
to

Trials with a site in Gdansk

20 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Gdansk, Katowice, Lublin, Skorzewo, Torun, Warsaw, Wałbrzych
2026-05-27
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Bielsko-Biala, Chrzanów, Gdansk, Gdynia, Lodz, Tarnów
2026-05-11
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 2
50
Gdansk, Wroclaw
2026-04-28
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
Novartis Pharmaceuticals
Phase 3
650
Krosno, Poznan, Gdansk
2026-04-16
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Gdansk, Torun, Warsaw
2025-11-10
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Gdansk, Katowice, Krakow, Opole
2025-10-03
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals
Phase 3
240
Gdansk, Gliwice, Krakow, Poznan, Warsaw
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Bydgoszcz, Gdansk, Lodz
2025-01-31
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Bialystok, Gdansk, Lodz
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Poznan, Gliwice, Gdansk, Lodz
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Gdansk, Lodz
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Gdansk
2022-07-07
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Nowy Targ, Ostrołęka, Sosnowiec, Bialystok, Bydgoszcz, Gdansk, Gdynia, Kielce
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Gdansk, Lodz, Poznan, Warsaw
2021-10-05
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Biała Podlaska, Gdansk, Katowice, Skorzewo, Torun
2021-04-09
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Gdansk, Poznan
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Gdansk, Krakow, Lodz, Poznan, Warsaw
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Bydgoszcz, Gdansk, Glogow Wielkopolski, Katowice, Kielce, Lodz, Poznan, Rzeszów
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Gdansk
2015-12-11
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/gdansk

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Gdansk that also match the filters currently applied.

How many clinical trials are recruiting in Gdansk?

8 of the 20 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gdansk), 20 studies
PhaseStudiesRecruitingShare
Phase 314670%
Phase 22110%
Phase 42010%
Phase 1105%
Phase 1/2115%

Most active sponsors

Lead sponsors with the most studies (Gdansk)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals208
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.